Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial of NT-I7 in COVID-19 (SPESELPIS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04501796
Recruitment Status : Recruiting
First Posted : August 6, 2020
Last Update Posted : May 3, 2022
Sponsor:
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID)
University of Nebraska
Information provided by (Responsible Party):
NeoImmuneTech

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The main purposes of this study is to determine the following in participants with mild coronavirus disease 2019 (COVID-19):

  • Safety of a single dose of NT-I7
  • The immunological effects of NT-I7 on peripheral lymphocyte counts in COVID-19 patients.

Condition or disease Intervention/treatment Phase
COVID-19 Drug: Double-Blind NT-I7 Drug: Double-Blind Placebo Phase 1

Detailed Description:
This is a multisite, double-blind, randomized, placebo-controlled, dose-escalating, phase 1 trial of NT-I7 with standard of care (SOC) versus placebo with SOC to evaluate the safety and efficacy of NT-I7 in adults with mild coronavirus disease 2019 (COVID-19). After determination of eligibility and baseline assessment, a single dose of the study agent (NT-I7 or placebo) will be administered after 1:1 randomization, along with SOC. Research blood collection will occur at baseline, days 3, 7, 14, 30, 60 and 90 days after administration. Primary and secondary evaluations will include assessment of adverse events (AEs), absolute lymphocyte count (ALC), and trajectory of other lymphocytes subsets: CD4, CD8, natural killer (NK), B, and mucosal-associated-invariant T (MAIT) cells. The final study visit will be at day 90 after the study agent administration. The investigators hypothesize that NT-I7 is safe for administration and preserves lymphocyte homeostasis in patients with mild COVID-19.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Double-Blind.
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized, Placebo-controlled, Phase 1, Single-dose, Dose-escalating Trial of Long-acting Recombinant Human IL-7 (NT-I7) for COVID-19
Actual Study Start Date : November 27, 2020
Estimated Primary Completion Date : August 2022
Estimated Study Completion Date : November 2022

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: NT-I7
NT-I7 will be administered once by IM injection within 24 hours of baseline (day 0). The treatment course pursued in all enrolled participants will be a single dose. Dosing will be staggered with at least 72 hours between each study participant.
 Drug: Double-Blind NT-I7
Administered by intramuscular (IM) injection
Other Names:
  • rhIL-7-hyFc
  • efineptakin alfa
Placebo Comparator: Placebo
Placebo will be administered once by IM injection within 24 hours of baseline (day 0). The treatment course pursued in all enrolled participants will be a single dose. Dosing will be staggered with at least 72 hours between each study participant.
 Drug: Double-Blind Placebo
Placebo


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Evaluate the safety of a single dose of NT-I7 in a dose escalation fashion [ Time Frame: Up to approximately 30 days ]
    Assessment of the number and severity of AEs possibly, probably, or definitely related to study drug evaluated at 7 and 30 days.


Secondary Outcome Measures :
  1. Evaluate the immunological effects of NT-I7 cumulatively for all doses on peripheral lymphocyte counts in COVID-19 patients. [ Time Frame: Up to approximately 30 days ]
    Assessment of the trajectory of ALC, CD4, CD8, NK, B, and MAIT cells measured at days 7, 14 and 30 after administration of NT-I7 or placebo compared to baseline values.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Individuals must meet all of the following criteria to be included in the study:
  • Laboratory-confirmed SARS-CoV-2 infection as determined by either a documented positive molecular assay/ other commercial or public health assay in any specimen collected < 5 days prior to screening or a documented positive molecular assay ≥ 5 days prior to screening and confirmed by polymerase chain reaction (PCR) at screening.
  • Illness of any duration with oxygen saturation > 93% at room air, heart rate ≤ 100 beats per minute at rest, and no evidence of respiratory distress with respiration rate < 20 breaths per minute.
  • Able to provide informed consent.
  • Aged ≥ 19 and ≤ 75 years.
  • Absolute Lymphocyte Count <1,500 lymphocytes/µL.
  • Avoid becoming pregnant or impregnate a partner through 90 days after study agent administration. Females must agree to 2 methods of contraception, and males to at least one method of contraception.
  • Not participate in any other clinical trial for an investigational therapy through day 30.

Exclusion Criteria:

  • Moderate to severe hypoxic respiratory failure requiring supplemental oxygen at rest, mechanical ventilation, ECMO, or any other noninvasive ventilation modality.
  • CRP >15 mg/L or D-dimer > 0.75 µg/mL.
  • Estimated glomerular filtration rate (eGFR) < 40 mL/min/1.73m2, or requiring dialysis.
  • AST/ALT > 3-times ULN, or total bilirubin > 1.5 times ULN (except if due to Gilbert's syndrome).
  • Pregnancy or breastfeeding.
  • Use of systemic corticosteroids or immunomodulant within 4 weeks prior to screening.
  • Receipt of an investigational agent or investigational use of a licensed agent within 16 weeks prior to screening.
  • HIV infection or underlying history of known or unknown primary or acquired immunodeficiency associated with lymphopenia and/or recurrent opportunistic infections.
  • Autoimmune disease requiring systemic treatment EXCEPT for vitiligo or endocrine disease (such as diabetes, thyroid disease, and adrenal disease) controlled by replacement therapy.
  • Malignancy requiring treatment 1 year prior to screening.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04501796


Contacts
Layout table for location contacts
Contact: Anela Kellogg 240-669-2877 anela.kellogg@nih.gov
Contact: Megan Anderson 301-761-7323 megan.anderson2@nih.gov

Locations
Layout table for location information
United States, Maryland
Nih/Niaid Recruiting
Bethesda, Maryland, United States, 20892
Contact: Anela Kellogg    240-669-2877    anela.kellogg@nih.gov   
United States, Nebraska
University of Nebraska Medical Center Recruiting
Omaha, Nebraska, United States, 68198
Contact: Sheryl Houston, BSN    402-836-9405    sheryl.houston@unmc.edu   
Sponsors and Collaborators
NeoImmuneTech
National Institute of Allergy and Infectious Diseases (NIAID)
University of Nebraska
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: NeoImmuneTech
ClinicalTrials.gov Identifier: NCT04501796    
Other Study ID Numbers: NIT-116 (SPESELPIS)
First Posted: August 6, 2020    Key Record Dates
Last Update Posted: May 3, 2022
Last Verified: December 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by NeoImmuneTech:
NT-I7 (efineptakin alfa, rhIL-7-hyFc)
COVID-19
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
 Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases